NCT00980460 2026-03-18
Risk-Based Therapy in Treating Younger Patients With Newly Diagnosed Liver Cancer
National Cancer Institute (NCI)
Phase 3 Active not recruiting
Clinical Trials
218 trialsNCT02567435 2026-03-17
Combination Chemotherapy With or Without Temsirolimus in Treating Patients With Intermediate Risk Rhabdomyosarcoma
National Cancer Institute (NCI)
Phase 3 Active not recruiting
NCT05440786 2026-03-12
CAMPFIRE: A Study of Abemaciclib (LY2835219) in Participants With Ewing's Sarcoma
Eli Lilly and Company
Phase 2 Active not recruiting
NCT02047474 2026-03-06
Combination Chemotherapy Before and After Surgery in Treating Patients With Localized Pancreatic Cancer
Yale University
Phase 2 Completed
NCT02890355 2026-03-05
FOLFIRI or Modified FOLFIRI and Veliparib as Second Line Therapy in Treating Patients With Metastatic Pancreatic Cancer
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT04094688 2026-03-03
SOLARIS
Alliance for Clinical Trials in Oncology
Phase 3 Active not recruiting
NCT04238819 2026-03-02
A Study of Abemaciclib (LY2835219) in Combination With Other Anti-Cancer Treatments in Children and Young Adult Participants With Solid Tumors, Including Neuroblastoma
Eli Lilly and Company
Phase 1/2 Completed
NCT04697628 2026-02-24
innovaTV 301
Seagen Inc.
Phase 3 Completed
NCT03794349 2026-02-18
Irinotecan Hydrochloride, Temozolomide, and Dinutuximab With or Without Eflornithine in Treating Patients With Relapsed or Refractory Neuroblastoma
Children's Oncology Group
Phase 2 Active not recruiting
NCT03365882 2026-02-10
S1613, Trastuzumab and Pertuzumab or Cetuximab and Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic HER2/Neu Amplified Colorectal Cancer That Cannot Be Removed by Surgery
SWOG Cancer Research Network
Phase 2 Completed
NCT03829462 2025-11-21
NEXT-REGIRI
Institut du Cancer de Montpellier - Val d'Aurelle
Phase 3 Active not recruiting
NCT02192359 2025-11-14
Carboxylesterase-Expressing Allogeneic Neural Stem Cells and Irinotecan Hydrochloride in Treating Patients With Recurrent High-Grade Gliomas
City of Hope Medical Center
Phase 1 Active not recruiting
NCT03184870 2025-10-09
A Study of BMS-813160 in Combination With Chemotherapy or Nivolumab in Participants With Advanced Solid Tumors
Bristol-Myers Squibb
Phase 1/2 Completed
NCT04008030 2025-10-03
CheckMate 8HW
Bristol-Myers Squibb
Phase 3 Active not recruiting
NCT05678257 2025-09-12
A Study of NUC-3373 in Combination With Other Agents in Patients With Colorectal Cancer
NuCana plc
Phase 2 Terminated
NCT05330429 2025-07-01
ELEVATE CRC
Gilead Sciences
Phase 2 Terminated
NCT05461794 2025-06-13
Study To Investigate the Efficacy and Safety of Sitravatinib in Combination With Tislelizumab in Participants With Esophageal Squamous Cell Carcinoma
BeiGene
Phase 2 Terminated
NCT02138617 2025-05-18
Genotype-Directed Study Of Irinotecan Dosing In FOLFIRI + BevacizumabTreated Metastatic Colorectal Cancer
UNC Lineberger Comprehensive Cancer Center
Phase 2 Completed
NCT01550510 2025-05-06
Research Study of IV Vitamin C in Combination With Irinotecan vs Irinotecan Alone for Advanced Colorectal CA
Thomas Jefferson University
Phase 1/2 Terminated
NCT03428958 2025-04-23
A Safety, Pharmacokinetic and Efficacy Study of NUC-3373 in Combination With Standard Agents Used in Colorectal Cancer Treatment
NuCana plc
Phase 1/2 Completed
NCT00545545 2025-03-19
Safety/Efficacy Study of Imprime PGG With Cetuximab in Patients With Recurrent/Progressive Colorectal Carcinoma
HiberCell, Inc.
Phase 1/2 Completed
NCT02489903 2025-03-17
RRx-001 in Lung Cancer, Ovarian Cancer and Neuroendocrine Tumors Prior to Re-administration of Platinum Based Doublet Regimens (QUADRUPLE THREAT)
EpicentRx, Inc.
Phase 2 Completed
NCT01814501 2025-02-05
Panitumumab and Chemotherapy in Patients With Advanced Colorectal Cancer After Prior Therapy With Bevacizumab
Ohio State University Comprehensive Cancer Center
Phase 2 Completed
NCT00248287 2025-01-29
CA225200
US Oncology Research
Phase 2 Active not recruiting
NCT02485834 2025-01-20
FDG-PET Directed Treatment in Improving Response in Patients With Locally Advanced Stomach or Gastroesophageal Junction Cancer
Alliance for Clinical Trials in Oncology
Phase 2 Terminated
NCT02975882 2025-01-14
Nanoparticle Albumin-Bound Rapamycin, Temozolomide, and Irinotecan Hydrochloride in Treating Pediatric Patients With Recurrent or Refractory Solid Tumors
Children's Oncology Group
Phase 1 Completed
NCT05546411 2024-12-17
A Trial of NIS793 With FOLFIRINOX in Pancreatic Cancer
Dana-Farber Cancer Institute
Phase 2 Terminated
NCT01905150 2024-12-11
Ph 2 Trial of Vitamin C & G-FLIP (Low Doses Gemcitabine, 5FU, Leucovorin, Irinotecan, Oxaliplatin) for Pancreatic Cancer
Bruckner Oncology
Phase 2 Completed
NCT03374254 2024-11-21
KEYNOTE-651
Merck Sharp & Dohme LLC
Phase 1 Completed
NCT03430843 2024-10-26
A Study of Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Participants With Advanced Esophageal Squamous Cell Carcinoma
BeiGene
Phase 3 Completed
NCT03879798 2024-10-10
DS-3201b and Irinotecan for Patients With Recurrent Small Cell Lung Cancer
Memorial Sloan Kettering Cancer Center
Phase 1/2 Terminated
NCT04117945 2024-09-27
Regorafenib, With Cetuximab or Panitumumab, for the Treatment of Unresectable, Locally Advanced, or Metastatic Colorectal Cancer
Academic and Community Cancer Research United
Phase 2 Active not recruiting
NCT03263429 2024-08-30
Novel PET/CT Imaging Biomarkers of CB-839 in Combination With Panitumumab and Irinotecan in Patients With Metastatic and Refractory RAS Wildtype Colorectal Cancer
Vanderbilt-Ingram Cancer Center
Phase 1/2 Completed
NCT01505608 2024-08-06
Randomized Efficacy Study of TPI 287 to Treat Primary Refractory or Early Relapsed Neuroblastoma
Milton S. Hershey Medical Center
Phase 1/2 Terminated
NCT03336216 2024-07-23
A Study of Cabiralizumab Given With Nivolumab With and Without Chemotherapy in Patients With Advanced Pancreatic Cancer
Bristol-Myers Squibb
Phase 2 Completed
NCT00891930 2024-07-17
Study to Evaluate Mechanisms of Acquired Resistance to Panitumumab
NantBioScience, Inc.
Phase 2 Completed
NCT02842580 2024-07-10
HIGH-LIGHT
Federation Francophone de Cancerologie Digestive
Phase 2 Terminated
NCT01941316 2024-05-09
Study of Carfilzomib With Irinotecan in Irinotecan-Sensitive Malignancies and Small Cell Lung Cancer Patients
Cancer Research and Biostatistics Clinical Trials Consortium
Phase 1/2 Completed
NCT00838578 2024-04-26
Phase I/II Study of KRN330 Plus Irinotecan in Patients With Metastatic Colorectal Cancer
Kyowa Kirin Co., Ltd.
Phase 1/2 Terminated
NCT01959139 2024-02-09
S1313, PEGPH20 in Treating Patients With Newly Diagnosed Metastatic Pancreatic Cancer
SWOG Cancer Research Network
Phase 1/2 Completed
NCT04074343 2024-02-02
TAS-102 and Irinotecan in 2L+ Gastric and Gastroesophageal Adenocarcinoma
University of California, Irvine
Phase 1 Completed
NCT03099382 2024-01-22
Study of SHR-1210 Versus Investigator's Choice of Chemotherapy for Participants With Advanced Esophageal Cancer
Jiangsu HengRui Medicine Co., Ltd.
Phase 3 Completed
NCT02928224 2023-12-21
BEACON CRC
Pfizer
Phase 3 Completed
NCT01897454 2023-12-05
Gemcitabine Hydrochloride, and Radiation Therapy in Patients With Borderline Resectable Pancreatic Cancer
Albert Einstein College of Medicine
Phase 2 Terminated
NCT02024607 2023-11-15
A Study of BBI608 in Combination With Standard Chemotherapies in Adult Patients With Advanced Gastrointestinal Cancer
Sumitomo Pharma America, Inc.
Phase 1/2 Completed
NCT02753127 2023-11-15
CanStem303C
Sumitomo Pharma America, Inc.
Phase 3 Completed
NCT01133990 2023-11-07
FOLFIRI Alone Versus FOLFIRI Plus Bevacizumab Versus FOLFIRI Plus E7820 as Second-Line Therapy in Patients With Locally Advanced or Metastatic Colorectal Cancer
Eisai Inc.
Phase 1/2 Terminated
NCT02095132 2023-09-26
Adavosertib and Irinotecan Hydrochloride in Treating Younger Patients With Relapsed or Refractory Solid Tumors
National Cancer Institute (NCI)
Phase 1/2 Completed
NCT01726582 2023-08-14
Pancreas Cancer: Molecular Profiling as a Guide to Therapy Before and After Surgery ("Personalized Medicine")
Medical College of Wisconsin
Phase 2 Completed
NCT04072445 2023-08-09
Trifluridine/Tipiracil and Irinotecan for the Treatment of Advanced Refractory Biliary Tract Cancer
Mayo Clinic
Phase 2 Completed